A commentary in The Lancet on the usefulness of inhaled budesonide for the early treatment of COVID-19 to prevent deterioration and other complications.

Key Messages

This commentary discusses the use of inhaled budesonide to prevent clinical deterioration in patients with COVID-19.

Clinical trials examining the use of inhaled budesonide for treating patients with early COVID-19 have shown promising results.

One of these clinical trials, called STOIC, took place in the UK and included 146 adults aged over 18 who had shown mild COVID-19 symptoms for seven days or less. 73 patients were given inhaled budesonide (two puffs of 400 micrograms twice a day until symptoms resolved) and 73 were given normal care.

Patients who took budesonide had a 91% reduced risk of hospitalization, or need to visit urgent care or the emergency department. In addition, patients taking budesonide had faster recovery times.

The Lancet Respiratory Medicine

Publication Date: April 9, 2021
Peer Reviewed: No
Publication Type: Review/Commentary/Letter
DOI: https://www.doi.org/10.1016/S2213-2600(21)00171-5

Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19

Alvar Agusti, Ferran Torres, Rosa Faner